Apoptosis

Why apoptosis matters

• Sculpts the embryo. Interdigital webbing in the human hand is removed by apoptosis between weeks 6 and 8 of gestation. Failure to apoptose those mesenchymal cells produces syndactyly (fused fingers). The same cellular sculpting separates the eyelids, hollows out the heart chambers, and closes the neural tube.
• Eliminates self-reactive immune cells. Roughly 95% of developing thymocytes die by apoptosis through negative selection — they bind self-antigen on thymic epithelium too strongly and are deleted. Loss of FasL (the gld mouse) or Fas (the lpr mouse) breaks peripheral tolerance and produces autoimmune lymphoproliferation.
• Cancer hallmark. Hanahan and Weinberg list evasion of apoptosis as one of six original hallmarks. Half of human tumors carry TP53 mutations; BCL-2 was the founding oncogene cloned from the t(14;18) follicular lymphoma translocation; MCL-1 amplification is among the most common copy-number gains across solid tumors.
• BH3 mimetics are now FDA-approved drugs. Venetoclax (ABT-199) achieves overall response rates near 80% in relapsed CLL patients with 17p deletion. The drug occupies the BH3-binding groove of BCL-2 with sub-nanomolar affinity, displacing pro-apoptotic BIM and BAX and triggering mitochondrial permeabilization within hours.
• Daily turnover. Each adult human runs roughly 50 to 70 billion cells through apoptosis every 24 hours — the rough mass of one's own body in cells over an 80-year lifespan, recycled. The intestinal epithelium replaces itself every 4 to 5 days, and apoptotic loss at the villus tip balances stem-cell proliferation in the crypt.
• Phagocytic clearance is silent. Externalized phosphatidylserine, recognized by Tim-4, BAI1, and MerTK on macrophages, drives engulfment within minutes. Removal so fast that histologists rarely see apoptotic bodies — apoptotic index in healthy tissue stays under 1% even in actively proliferating epithelia.
• Anti-inflammatory by design. Apoptotic-cell engulfment actively suppresses inflammation by inducing TGF-beta and IL-10 in the engulfing macrophage. This is the opposite of necrotic-cell engulfment, which releases DAMPs and activates IL-1 and TNF — a key reason apoptosis evolved as the default disposal program.

Common misconceptions

• Apoptosis is just "cell suicide". The cell does dismantle itself, but the surrounding tissue cooperates: macrophages and neighboring epithelial cells use specialized receptors (Tim-4, BAI1, MerTK, integrin alpha-v-beta-3) to find and engulf the apoptotic body. Without that pickup, secondary necrosis follows and inflammation breaks out.
• All caspases are pro-apoptotic. Caspase-1, -4, -5 (in humans) and -11 (in mice) drive pyroptosis and inflammation, not apoptosis. Caspase-14 is required for keratinocyte differentiation. Caspase-8 has scaffold roles in necroptosis suppression — knockout mice die from rampant RIPK3-driven necroptosis, not loss of apoptosis.
• Cytochrome c release is reversible. Mitochondrial outer membrane permeabilization (MOMP) is the point of no return in nearly all cell types. Even if caspases are inhibited downstream, the cell dies by caspase-independent mechanisms (AIF release, mitochondrial dysfunction) within hours. The historical drug zVAD-fmk demonstrates this: it blocks caspases but cells still die after MOMP, just more slowly and with necrotic features.
• BCL-2 always promotes survival. The BCL-2 family is named after its first member but contains both pro-survival (BCL-2, BCL-xL, MCL-1, A1, BCL-W) and pro-apoptotic members (multidomain BAX/BAK; BH3-only BIM, BID, BAD, PUMA, NOXA, BMF, HRK, BIK). The balance — not any single protein — determines outcome.
• DNA laddering proves apoptosis. The 180-bp nucleosomal DNA ladder on agarose gels is suggestive but not definitive. Caspase-activated DNase (CAD/DFF40) cleaves chromatin between nucleosomes, but late necrotic cells also produce smeared DNA degradation, and some apoptotic deaths in lymphocytes show no laddering at all. Annexin V/PI flow cytometry plus caspase-3 cleavage is the modern gold standard.
• Apoptosis is exclusively intrinsic or exclusively extrinsic. The two pathways converge. In type II cells (hepatocytes, pancreatic beta cells), extrinsic Fas signaling cannot kill on its own — caspase-8 must cleave BID into tBID, which then permeabilizes mitochondria via BAX/BAK to amplify the signal. Loss of BID rescues these cells from FasL-induced death.

How apoptosis works

The execution of apoptosis is a controlled proteolytic cascade. Two upstream pathways converge on executioner caspases. The intrinsic (mitochondrial) pathway begins when intracellular stress — DNA damage, ER stress, growth-factor withdrawal, hypoxia — upregulates or activates BH3-only proteins (BIM, BID, BAD, PUMA, NOXA, BMF). These proteins either directly activate the multidomain effectors BAX and BAK or neutralize the pro-survival guardians BCL-2, BCL-xL, MCL-1, A1, BCL-W. Once unrestrained, BAX translocates from cytosol to the mitochondrial outer membrane, oligomerizes with BAK, and forms pores roughly 25 to 100 nm across that release cytochrome c, Smac/DIABLO, AIF, and Omi/HtrA2 into the cytosol within seconds. Cytochrome c — about 1000 molecules per mitochondrion in a HeLa cell — binds Apaf-1 in a dATP-dependent manner; seven Apaf-1 monomers wheel-spoke into the apoptosome, which recruits and activates initiator caspase-9.

The extrinsic (death receptor) pathway begins at the plasma membrane. TNF-alpha, FasL (CD95L), or TRAIL trimerizes its receptor (TNFR1, Fas/CD95, DR4/DR5), which clusters death domains on its cytoplasmic tail and recruits the adaptor FADD. FADD's death effector domain (DED) recruits procaspase-8 (and -10) into a death-inducing signaling complex (DISC). Forced dimerization on the DISC activates caspase-8 by autocleavage. In type I cells (most thymocytes), caspase-8 directly cleaves and activates executioner caspase-3. In type II cells (hepatocytes, beta cells), caspase-8 cleaves the BH3-only protein BID into tBID, which translocates to mitochondria and engages the intrinsic pathway for amplification.

Both upstream branches activate executioner caspases (-3, -6, -7), which cleave hundreds of substrates after Asp residues to disassemble the cell. ICAD is cleaved, releasing CAD nuclease, which fragments chromatin into nucleosomal multiples (the 180-bp ladder). Lamins A/B/C are cleaved, collapsing the nuclear envelope. ROCK1 is cleaved into a constitutively active kinase that drives actomyosin contraction and the dramatic membrane blebbing. Gelsolin is cleaved, severing actin filaments. Phospholipid scramblases flip phosphatidylserine to the outer leaflet, broadcasting the eat-me signal. The cell shrinks, fragments into apoptotic bodies of roughly 1 to 5 µm, and is engulfed by macrophages or neighboring cells via Tim-4/MerTK/BAI1 within minutes.

Apoptosis vs necrosis vs pyroptosis vs ferroptosis

Feature	Apoptosis	Necrosis (oncosis)	Pyroptosis	Ferroptosis
Trigger	BH3-only / death receptors	Energy failure, severe damage	Inflammasomes (NLRP3, AIM2)	Iron-dependent lipid peroxidation
Key proteases	Caspases-3/7/8/9	None (passive)	Caspase-1, gasdermin D	None (lipid radical chemistry)
Membrane fate	Intact, blebs outward	Ruptures, swells	Gasdermin pores, lyses	Lipid peroxide-driven rupture
Inflammation	Silent (anti-inflammatory)	High (DAMPs)	Very high (IL-1β, IL-18)	Variable (oxidized lipids signal)
DNA	180-bp laddering	Random degradation	Random degradation	Largely intact
Energy required	ATP-dependent	None	ATP-dependent	None directly
Drug target	BCL-2 (venetoclax)	RIPK1/3 (necrostatins)	NLRP3 (MCC950)	GPX4 (RSL3, erastin)

Intrinsic vs extrinsic apoptosis pathway

Property	Intrinsic (mitochondrial)	Extrinsic (death receptor)
Trigger	DNA damage, ER stress, growth-factor loss, hypoxia	FasL, TNF-α, TRAIL on neighbor cell or immune cell
Initial sensors	p53, ATM/ATR, JNK → BH3-only proteins	Death receptors: Fas/CD95, TNFR1, DR4, DR5
Initiator caspase	Caspase-9 (apoptosome)	Caspase-8/-10 (DISC)
Adaptor	Apaf-1 (CARD)	FADD (DED + DD)
Cytochrome c required	Yes, plus Smac/DIABLO	Only in type II cells via tBID
BCL-2 family essential	Yes, BAX/BAK obligatory	No (type I); yes (type II)
Main physiologic role	Tissue homeostasis, embryonic sculpting	Immune-mediated killing, T-cell contraction
Mouse knockout phenotype	Bax/Bak DKO: persistent interdigital webs, lymphocyte hyperplasia	Fas-deficient (lpr): autoimmune lymphoproliferation

Famous experiments

• Kerr, Wyllie, Currie (1972). Electron microscopy of dying hepatocytes after ischemia and of regressing tumors revealed a stereotyped morphology — pyknotic nuclei, cytoplasmic shrinkage, blebbing, phagocytic engulfment — distinct from necrosis. They named the process apoptosis (Greek: leaves falling from a tree) in British Journal of Cancer 26: 239–257. Citations now exceed 35,000.
• Horvitz lab on C. elegans. Of the 1090 somatic cells generated during hermaphrodite development, exactly 131 die at predictable lineage positions. Mutations in ced-3 (caspase) and ced-4 (Apaf-1) prevent all 131 deaths; ced-9 (BCL-2) loss causes ectopic deaths. The work — published 1986 to 1992 — won the 2002 Nobel Prize for Horvitz, Brenner, and Sulston.
• Wang lab cytochrome c discovery (1996). Xiaodong Wang's group used a cell-free Xenopus extract to fractionate the missing factor required for caspase-3 activation downstream of mitochondria. The factor turned out to be cytochrome c — a respiratory chain component already known for 70 years, now revealed to moonlight as the apoptotic trigger that nucleates Apaf-1 into the apoptosome.
• Fas/FasL system in mice. The lpr (Fas mutation) and gld (FasL mutation) mouse strains develop massive lymphadenopathy, splenomegaly, and lupus-like autoimmunity. Crossing them confirmed that the same pathway operates from both sides. Human ALPS (autoimmune lymphoproliferative syndrome) patients carry FAS mutations and recapitulate the lpr phenotype.
• Venetoclax clinical trials. Phase 2 trials in 17p-deleted relapsed CLL (M13-982, 2016) showed an overall response rate of 79%, with complete remissions even in poor-prognosis disease previously considered untreatable. The drug is a synthetic BH3 mimetic that binds BCL-2 with Ki ≈ 0.01 nM, displacing BIM. AbbVie received FDA approval in April 2016 for relapsed CLL.